凝血酶抑制剂治疗脑出血疗效观察

Clinical efficacy of thrombin inhibitor treatment in intracerebral hemorrhage

目的:探讨脑出血(ICH)后凝血酶抑制剂脉血康对抑制血肿增大和改善临床转归的价值。方法:将58例ICH患者随机分为对照组和脉血康治疗组,在治疗前后通过影像学、实验室检查、神经功能评分对两组患者的血肿变化和转归情况进行比较。结果:治疗4周后,治疗组和对照组在血肿体积、病变总体积、临床转归之间差异有显著性。结论:脉血康能够显著减轻ICH后血肿增大,减少ICH病变总体积,明显的改善临床转归。

Objective：To investigate the values of thrombin inhibitor Maixuekang capsules given after the onset of intracerebral hemorrhage for inhibiting hematoma enlargement and improving clinical outcome.Methods：The fifty-eight patients with intracerebral hemorrhage were randomly allocated into control and treatment groups.The changes of hematoma and clinical outcome were compared after the treatment of four weeks by using brain CT scan,laboratory examination and neurological rating scales.Results：There were significant differences in the volume of hematoma, total volume of lesions and clinical outcome between the two groups.Conclusion：Thrombin inhibitor Maixuekang capsules may dramatically reduce hematoma enlargement,decrease the total volume of lesions and improve clinical outcome significantly.